Short Interest in Mainz Biomed (NASDAQ:MYNZ) Drops By 33.7%

Mainz Biomed (NASDAQ:MYNZ) saw a significant decrease in short interest in the month of June. As of June 15th, there was short interest totalling 282,200 shares, a decrease of 33.7% from the May 31st total of 425,700 shares. Based on an average daily volume of 206,100 shares, the short-interest ratio is currently 1.4 days. Approximately 1.7% of the company’s shares are short sold.

Analysts Set New Price Targets

MYNZ has been the subject of a number of recent analyst reports. HC Wainwright lowered their price target on Mainz Biomed from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Wednesday, March 6th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Mainz Biomed in a research note on Friday, April 12th.

Mainz Biomed Price Performance

Shares of MYNZ opened at $0.47 on Friday. The company has a 50-day simple moving average of $0.68 and a two-hundred day simple moving average of $0.92. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.91 and a current ratio of 0.97. Mainz Biomed has a one year low of $0.35 and a one year high of $5.01.

Mainz Biomed (NASDAQ:MYNZ) last issued its quarterly earnings results on Tuesday, April 9th. The company reported ($0.24) earnings per share for the quarter. The firm had revenue of $0.22 million during the quarter. Mainz Biomed had a negative return on equity of 488.05% and a negative net margin of 2,934.82%. Research analysts anticipate that Mainz Biomed will post -0.88 earnings per share for the current fiscal year.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.